Details

Autor(en) / Beteiligte

• Benkel, Tobias
• Zimmermann, Mirjam
• Zeiner, Julian
• Bravo, Sergi
• Merten, Nicole
• Lim, Victor Jun Yu
• Matthees, Edda Sofie Fabienne
• Drube, Julia
• Miess-Tanneberg, Elke
• Malan, Daniela
• Szpakowska, Martyna
• Monteleone, Stefania
• Grimes, Jak
• Koszegi, Zsombor
• Lanoiselée, Yann
• O'Brien, Shannon
• Pavlaki, Nikoleta
• Dobberstein, Nadine
• Inoue, Asuka
• Nikolaev, Viacheslav
• Calebiro, Davide
• Chevigné, Andy
• Sasse, Philipp
• Schulz, Stefan
• Hoffmann, Carsten
• Kolb, Peter
• Waldhoer, Maria
• Simon, Katharina
• Gomeza, Jesus
• Kostenis, Evi

Titel

How Carvedilol activates β 2 -adrenoceptors

Ist Teil von

• Nature communications, 2022-11, Vol.13 (1), p.7109

Ort / Verlag

England

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Carvedilol is among the most effective β-blockers for improving survival after myocardial infarction. Yet the mechanisms by which carvedilol achieves this superior clinical profile are still unclear. Beyond blockade of β -adrenoceptors, arrestin-biased signalling via β -adrenoceptors is a molecular mechanism proposed to explain the survival benefits. Here, we offer an alternative mechanism to rationalize carvedilol's cellular signalling. Using primary and immortalized cells genome-edited by CRISPR/Cas9 to lack either G proteins or arrestins; and combining biological, biochemical, and signalling assays with molecular dynamics simulations, we demonstrate that G proteins drive all detectable carvedilol signalling through β ARs. Because a clear understanding of how drugs act is imperative to data interpretation in basic and clinical research, to the stratification of clinical trials or to the monitoring of drug effects on the target pathway, the mechanistic insight gained here provides a foundation for the rational development of signalling prototypes that target the β-adrenoceptor system.